Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

Highlights • Liraglutide and lixisenatide protect mice from MPTP toxicity, a model of Parkinson’s disease. • Both drugs are currently on the market to treat type 2 diabetes. • Neuroprotective effects in PD are shown for the first time here. • Clinical trials are in preparation in Parkinson’s patient...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuroscience 2015-09, Vol.303, p.42-50
Hauptverfasser:	Liu, W, Jalewa, J, Sharma, M, Li, G, Li, L, Hölscher, C
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Animals apoptosis Apoptosis - drug effects basal ganglia Basal Ganglia - drug effects Basal Ganglia - metabolism Catalepsy - chemically induced Disease Models, Animal Dopaminergic Neurons - metabolism growth factor incretin insulin Liraglutide - administration & dosage Male Mice Mice, Inbred C57BL Motor Activity - drug effects neurodegeneration Neurology Neuroprotective Agents - administration & dosage Parkinsonian Disorders - physiopathology Parkinsonian Disorders - prevention & control Peptides - administration & dosage Rotarod Performance Test Substantia Nigra - drug effects Substantia Nigra - metabolism Tyrosine 3-Monooxygenase - metabolism Venoms - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Liraglutide and lixisenatide protect mice from MPTP toxicity, a model of Parkinson’s disease. • Both drugs are currently on the market to treat type 2 diabetes. • Neuroprotective effects in PD are shown for the first time here. • Clinical trials are in preparation in Parkinson’s patients, testing these drugs.
ISSN:	0306-4522 1873-7544
DOI:	10.1016/j.neuroscience.2015.06.054